Operating Segments (Tables)

3 Months Ended

Mar. 31, 2016

Operating Segments [Abstract]

Summary of segmental information

	Three Months Ended March 31,
	2016			2015
Contract/Grant Revenue
Vaccines/BioDefense	$	2,630,986		$	802,314
BioTherapeutics		-			13,972
Total	$	2,630,986		$	816,286
Income/(Loss) from Operations
Vaccines/BioDefense	$	317,991		$	84,681
BioTherapeutics		(1,245,585	)		(764,876	)
Corporate		(978,111	)		(878,072	)
Total	$	(1,905,705	)	$	(1,558,267	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	10,019		$	9,786
BioTherapeutics		10,433			48,374
Corporate		2,155			1,766
Total	$	22,607		$	59,926
Interest Income/(Expense)
Corporate	$	(3,885	)	$	561
Share-Based Compensation
Vaccines/BioDefense	$	28,006		$	24,592
BioTherapeutics		34,832			29,256
Corporate		73,573			88,177
Total	$	136,411		$	142,025

	As of March 31, 2016		As of  December 31,  2015
Identifiable Assets
Vaccines/BioDefense	$	1,150,768	$	2,123,676
BioTherapeutics		70,274		76,183
Corporate		4,369,978		5,187,263
Total	$	5,591,020	$	7,387,122